Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme
Author:
Publisher
Elsevier BV
Subject
General Medicine,Biochemistry
Reference40 articles.
1. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle[ast];Hershko;Cell Death Differ.,2005
2. Velcade®: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy;Kane;Oncologist,2003
3. Development of the proteasome inhibitor Velcade™ (Bortezomib);Adams;Cancer Invest.,2004
4. Bortezomib: proteasome inhibition as an effective anticancer therapy;Richardson;Future Oncol.,2005
5. Nedd8 on cullin: building an expressway to protein destruction;Pan;Oncogene,2004
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy;Biomedicine & Pharmacotherapy;2024-10
2. Protein neddylation and its role in health and diseases;Signal Transduction and Targeted Therapy;2024-04-05
3. Discovery of the 2,4-disubstituted quinazoline derivative as a novel neddylation inhibitor for tumor therapy;Bioorganic Chemistry;2024-04
4. Advancements in colorectal cancer research: Unveiling the cellular and molecular mechanisms of neddylation (Review);International Journal of Oncology;2024-02-21
5. Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions;Journal of Hematology & Oncology;2023-07-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3